Auvelity Improves Cognitive, Physical Functioning in MDD Patients
On December 7, 2022, Axsome Therapeutics, Inc., announced that treatment with the recently FDA-approved agent Auvelity (dextromethorphan hydrobromide-bupropion hydrochloric acid) produced swift, substantial, and durable improvements in cognitive and physical functioning in the EVOLVE open-label trial in major depressive disorder (MDD). Treatment with Auvelity also resulted in diminished disability. Read more.

Gut Microbiota, Fecal MicroRNA Correlation in MDD Patients
Research reveals that microbiota-gut-brain axis signaling plays a fundamental role in mood disorders. Additionally, microRNAs, which are small, single-stranded RNAs about 22 nucleotides long, also have vital roles in regulating gene expression at the post-transcriptional level and are highly implicated in the certain human diseases. Learn more about these correlations in patients with major depressive disorder (MDD).